share_log

Ladenburg Thalmann Maintains Buy on TG Therapeutics, Raises Price Target to $40

Benzinga ·  May 2 21:04

Ladenburg Thalmann analyst Matthew Kaplan maintains TG Therapeutics (NASDAQ:TGTX) with a Buy and raises the price target from $39 to $40.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment